Table of Contents Author Guidelines Submit a Manuscript
Journal of Lipids
Volume 2011, Article ID 674968, 13 pages
http://dx.doi.org/10.1155/2011/674968
Review Article

Ceramide in Cystic Fibrosis: A Potential New Target for Therapeutic Intervention

1Human Genetics, McGill University Health Center Research Institute, 1650 Cedar Avenue L11-218, Montreal, QC, Canada H3G 1A4
2Institute of Immunology, Central University of Venezuela, Apartado Postale 50109, Caracas 1050A, Venezuela
3Departments of Medicine and Human Genetics, McGill University Health Center Research Institute, 1650 Cedar Avenue L11-218, Montreal, QC, Canada H3G 1A4

Received 28 July 2010; Revised 4 October 2010; Accepted 11 November 2010

Academic Editor: Xianlin Han

Copyright © 2011 Gabriella Wojewodka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. Berg, A. Kallner, E. Kusoffsky, and B. Strandvik, “Fatty acid supplementation in cystic fibrosis,” Monographs in Paediatrics, vol. 10, pp. 1–4, 1979. View at Google Scholar · View at Scopus
  2. S. D. Freedman, M. H. Katz, E. M. Parker, M. Laposata, M. Y. Urman, and J. G. Alvarez, “A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 24, pp. 13995–14000, 1999. View at Google Scholar · View at Scopus
  3. S. M. Moskowitz, J. F. Chmiel, D. L. Sternen et al., “Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders,” Genetics in Medicine, vol. 10, no. 12, pp. 851–868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Guilbault, G. Wojewodka, Z. Saeed et al., “Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide,” American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 1, pp. 100–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. A. Flume, B. P. O'Sullivan, K. A. Robinson et al., “Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 10, pp. 957–969, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. E. C. M. Sikkens, D. L. Cahen, E. J. Kuipers, and M. J. Bruno, “Pancreatic enzyme replacement therapy in chronic pancreatitis,” Best Practice and Research: Clinical Gastroenterology, vol. 24, no. 3, pp. 337–347, 2010. View at Publisher · View at Google Scholar
  7. D. S. Hardin, “Pharmacotherapy of diabetes in cystic fibrosis patients,” Expert Opinion on Pharmacotherapy, vol. 11, no. 5, pp. 771–778, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Guilbault, J. B. De Sanctis, G. Wojewodka et al., “Fenretinide corrects newly found ceramide deficiency in cystic fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 38, no. 1, pp. 47–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Zheng, J. Kollmeyer, H. Symolon et al., “Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy,” Biochimica et Biophysica Acta, vol. 1758, no. 12, pp. 1864–1884, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Simons and D. Toomre, “Lipid rafts and signal transduction,” Nature Reviews Molecular Cell Biology, vol. 1, no. 1, pp. 31–39, 2000. View at Google Scholar · View at Scopus
  11. B. Stancevic and R. Kolesnick, “Ceramide-rich platforms in transmembrane signaling,” FEBS Letters, vol. 584, no. 9, pp. 1728–1740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Mathlas, L. A. Pena, and R. N. Kolesnick, “Signal transduction of stress via ceramide,” Biochemical Journal, vol. 335, no. 3, pp. 465–480, 1998. View at Google Scholar · View at Scopus
  13. C. Perrotta and E. Clementi, “Biological roles of acid and neutral sphingomyelinases and their regulation by nitric oxide,” Physiology, vol. 25, no. 2, pp. 64–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Ohlsson, L. Hjelte, M. Hühn et al., “Expression of intestinal and lung alkaline sphingomyelinase and neutral ceramidase in cystic fibrosis f508del transgenic mice,” Journal of Pediatric Gastroenterology and Nutrition, vol. 47, no. 5, pp. 547–554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. E. Cremesti and A. S. Fischl, “Current methods for the identification and quantitation of ceramides: an overview,” Lipids, vol. 35, no. 9, pp. 937–945, 2000. View at Google Scholar · View at Scopus
  16. J. Bielawski, Z. M. Szulc, Y. A. Hannun, and A. Bielawska, “Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry,” Methods, vol. 39, no. 2, pp. 82–91, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. K. Perry, Y. A. Hannun, V. M. Dixit et al., “The use of diglyceride kinase for quantifying ceramide,” Trends in Biochemical Sciences, vol. 24, no. 6, pp. 226–227, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Watts, M. Gu, A. J. Polverino, S. D. Patterson, and R. Aebersold, “Fas-induced apoptosis of T cells occurs independently of ceramide generation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 14, pp. 7292–7296, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. J. D. Watts, R. Aebersold, A. J. Polverino, S. D. Patterson, and M. Gu, “Ceramide second messengers and ceramide assays,” Trends in Biochemical Sciences, vol. 24, no. 6, p. 228, 1999. View at Google Scholar · View at Scopus
  20. A. Bielawska, D. K. Perry, and Y. A. Hannun, “Determination of ceramides and diglycerides by the diglyceride kinase assay,” Analytical Biochemistry, vol. 298, no. 2, pp. 141–150, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Brodlie, M. C. McKean, G. E. Johnson et al., “Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 3, pp. 369–375, 2010. View at Publisher · View at Google Scholar
  22. V. Teichgräber, M. Ulrich, N. Endlich et al., “Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis,” Nature Medicine, vol. 14, no. 4, pp. 382–391, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. A. Cowart, Z. Szulc, A. Bielawska, and Y. A. Hannun, “Structural determinants of sphingolipid recognition by commercially available anti-ceramide antibodies,” Journal of Lipid Research, vol. 43, no. 12, pp. 2042–2048, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. P. W. Wertz and D. T. Downing, “Ceramides of pig epidermis: structure determination,” Journal of Lipid Research, vol. 24, no. 6, pp. 759–765, 1983. View at Google Scholar · View at Scopus
  25. G. Vielhaber, L. Brade, B. Lindner et al., “Mouse anti-ceramide antiserum: a specific tool for the detection of endogenous ceramide,” Glycobiology, vol. 11, no. 6, pp. 451–457, 2001. View at Google Scholar · View at Scopus
  26. M. Gu, J. L. Kerwin, J. D. Watts, and R. Aebersold, “Ceramide profiling of complex lipid mixtures by electrospray ionization mass spectrometry,” Analytical Biochemistry, vol. 244, no. 2, pp. 347–356, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Fillet, J. C. Van Heugen, A. C. Servais, J. De Graeve, and J. Crommen, “Separation, identification and quantitation of ceramides in human cancer cells by liquid chromatography-electrospray ionization tandem mass spectrometry,” Journal of Chromatography A, vol. 949, no. 1-2, pp. 225–233, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. A. H. Merrill, M. C. Sullards, J. C. Allegood, S. Kelly, and E. Wang, “Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry,” Methods, vol. 36, no. 2, pp. 207–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Bielawski, J. S. Pierce, J. Snider, B. Rembiesa, Z. M. Szulc, and A. Bielawska, “Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry,” Methods in molecular biology (Clifton, N.J.), vol. 579, pp. 443–467, 2009. View at Google Scholar · View at Scopus
  30. J. Folch, M. Lees, and G. H. Sloane Stanely, “A simple method for the isolation and purification of total lipides from animal tissues,” The Journal of Biological Chemistry, vol. 226, no. 1, pp. 497–509, 1957. View at Google Scholar · View at Scopus
  31. E. G. Bligh and W. J. Dyer, “A rapid method of total lipid extraction and purification,” Canadian Journal of Biohemistry and Physiology, vol. 37, no. 8, pp. 911–917, 1959. View at Google Scholar · View at Scopus
  32. X. Han and X. Jiang, “A review of lipidomic technologies applicable to sphingolipidomics and their relevant applications,” European Journal of Lipid Science and Technology, vol. 111, no. 1, pp. 39–52, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. C. S. Ejsing, J. L. Sampaio, V. Surendranath et al., “Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2136–2141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. C. Davies and D. Bilton, “Bugs, biofilms, and resistance in cystic fibrosis,” Respiratory Care, vol. 54, no. 5, pp. 628–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Guilbault, J. P. Novak, P. Martin et al., “Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls,” Physiological Genomics, vol. 25, no. 2, pp. 179–193, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Z. Khan, J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, and D. W. H. Riches, “Early pulmonary inflammation in infants with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 4, pp. 1075–1082, 1995. View at Google Scholar · View at Scopus
  37. T. L. Noah, H. R. Black, P. W. Cheng, R. E. Wood, and M. W. Leigh, “Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis,” Journal of Infectious Diseases, vol. 175, no. 3, pp. 638–647, 1997. View at Google Scholar · View at Scopus
  38. C. Verhaeghe, K. Delbecque, L. de Leval, C. Oury, and V. Bours, “Early inflammation in the airways of a cystic fibrosis foetus,” Journal of Cystic Fibrosis, vol. 6, no. 4, pp. 304–308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Rottner, J. M. Freyssinet, and M. C. Martínez, “Mechanisms of the noxious inflammatory cycle in cystic fibrosis,” Respiratory Research, vol. 10, no. 1, pp. 23–33, 2009. View at Google Scholar · View at Scopus
  40. J. Bérubé, L. Roussel, L. Nattagh, and S. Rousseau, “Loss of cystic fibrosis transmembrane conductance regulator function enhances activation of p38 and erk mapks, increasing interleukin-6 synthesis in airway epithelial cells exposed to Pseudomonas aeruginosa,” Journal of Biological Chemistry, vol. 285, no. 29, pp. 22299–22307, 2010. View at Publisher · View at Google Scholar
  41. T. P. Dean, Y. Dai, J. K. Shute, M. K. Church, and J. O. Warner, “Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis,” Pediatric Research, vol. 34, no. 2, pp. 159–161, 1993. View at Google Scholar · View at Scopus
  42. M. Bodas and N. Vij, “The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential,” Discovery Medicine, vol. 9, no. 47, pp. 346–356, 2010. View at Google Scholar
  43. N. Vij, S. Mazur, and P. L. Zeitlin, “CFTR is a negative regulator of NFkappaB mediated innate immune response,” PLoS One, vol. 4, no. 2, Article ID e4664, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Chiba, A. Masuda, Y. Yoshikai, and T. Matsuguchi, “Ceramide inhibits LPS-induced production of IL-5, IL-10, and IL-13 from mast cells,” Journal of Cellular Physiology, vol. 213, no. 1, pp. 126–136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. K. A. Rozenova, G. M. Deevska, A. A. Karakashian, and M. N. Nikolova-Karakashian, “Studies on the role of acid sphingomyelinase and ceramide in the regulation of tumor necrosis factor α (TNFα)-converting enzyme activity and TNFα secretion in macrophages,” Journal of Biological Chemistry, vol. 285, no. 27, pp. 21103–21113, 2010. View at Publisher · View at Google Scholar
  46. R. T. Dobrowsky, C. Kamibayashi, M. C. Mumby, and Y. A. Hannun, “Ceramide activates heterotrimeric protein phosphatase 2A,” Journal of Biological Chemistry, vol. 268, no. 21, pp. 15523–15530, 1993. View at Google Scholar · View at Scopus
  47. T. T. Cornell, V. Hinkovska-Galcheva, L. Sun et al., “Ceramide-dependent PP2A regulation of TNFα-induced IL-8 production in respiratory epithelial cells,” American Journal of Physiology, vol. 296, no. 5, pp. L849–L856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Kitatani, K. Sheldon, V. Anelli et al., “Acid β-glucosidase 1 counteracts p38δ-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid,” Journal of Biological Chemistry, vol. 284, no. 19, pp. 12979–12988, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Van Bambeke, C. Gerbaux, J. M. Michot, M. B. d'Yvoire, J. P. Montenez, and P. M. Tulkens, “Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin,” Journal of Antimicrobial Chemotherapy, vol. 42, no. 6, pp. 761–767, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. G. John, A. Ö. Yildirim, B. K. Rubin, D. C. Gruenert, and M. O. Henke, “TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 42, no. 4, pp. 424–431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. M. P. Kowalski and G. B. Pier, “Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation,” Journal of Immunology, vol. 172, no. 1, pp. 418–425, 2004. View at Google Scholar · View at Scopus
  52. M. Gadjeva, C. Paradis-Bleau, G. P. Priebe, R. Fichorova, and G. B. Pier, “Caveolin-1 modifies the immunity to Pseudomonas aeruginosa,” Journal of Immunology, vol. 184, no. 1, pp. 296–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Xu, A. Krause, H. Hamai, B.-G. Harvey, T. S. Worgall, and S. Worgall, “Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA,” PLoS One, vol. 5, no. 6, Article ID e11004, 2010. View at Publisher · View at Google Scholar
  54. H. Fischer, P. Ellström, K. Ekström, L. Gustafsson, M. Gustafsson, and C. Svanborg, “Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4,” Cellular Microbiology, vol. 9, no. 5, pp. 1239–1251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Grassmé, V. Jendrossek, A. Riehle et al., “Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts,” Nature Medicine, vol. 9, no. 3, pp. 322–330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Kerbiriou, L. Teng, N. Benz, P. Trouvé, and C. Férec, “The calpain, caspase 12, caspase 3 cascade leading to apoptosis is altered in F508del-CFTR expressing cells,” PloS One, vol. 4, no. 12, Article ID e8436, 2009. View at Google Scholar · View at Scopus
  57. C. L. Cannon, M. P. Kowalski, K. S. Stopak, and G. B. Pier, “Pseudomonas aeruginosa-induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 2, pp. 188–197, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. S. N. Lavrentiadou, C. Chan, T. Kawcak et al., “Ceramide-mediated apoptosis in lung epithelial cells is regulated by glutathione,” American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 6, pp. 676–684, 2001. View at Google Scholar · View at Scopus
  59. D. Duan, A. Sehgal, J. Yao, and J. F. Engelhardt, “Lef1 transcription factor expression defines airway progenitor cell targets for In utero gene therapy of submucosal gland in cystic fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 18, no. 6, pp. 750–758, 1998. View at Google Scholar · View at Scopus
  60. L. M. Obeid, C. M. Linardic, L. A. Karolak, and Y. A. Hannun, “Programmed cell death induced by ceramide,” Science, vol. 259, no. 5102, pp. 1769–1771, 1993. View at Google Scholar · View at Scopus
  61. A. L. Hilchie, S. J. Furlong, K. Sutton et al., “Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria,” Nutrition and Cancer, vol. 62, no. 3, pp. 379–389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Sauane, Z. Z. Su, R. Dash et al., “Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis,” Journal of Cellular Physiology, vol. 222, no. 3, pp. 546–555, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Salma, E. Lafont, N. Therville et al., “The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism,” Biochemical Pharmacology, vol. 78, no. 5, pp. 477–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. J. D. Qin, L. Weiss, S. Slavin, S. Gatt, and A. Dagan, “Synthetic, non-natural analogs of ceramide elevate cellular ceramide, inducing apoptotic death to prostate cancer cells and eradicating tumors in mice,” Cancer Investigation, vol. 28, no. 5, pp. 535–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Hail, H. J. Kim, and R. Lotan, “Mechanisms of fenretinide-induced apoptosis,” Apoptosis, vol. 11, no. 10, pp. 1677–1694, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. B. J. Kroesen, S. Jacobs, B. J. Pettus et al., “BcR-induced apoptosis involves differential regulation of C and C-ceramide formation and sphingolipid-dependent activation of the proteasome,” Journal of Biological Chemistry, vol. 278, no. 17, pp. 14723–14731, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Osawa, H. Uchinami, J. Bielawski, R. F. Schwabe, Y. A. Hannun, and D. A. Brenner, “Roles for C-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-α,” Journal of Biological Chemistry, vol. 280, no. 30, pp. 27879–27887, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. B. J. Maurer, L. S. Metelitsa, R. C. Seeger, M. C. Cabot, and C. P. Reynolds, “Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4- hydroxyphenyl)-retinamide in neuroblastoma cell lines,” Journal of the National Cancer Institute, vol. 91, no. 13, pp. 1138–1146, 1999. View at Google Scholar · View at Scopus
  69. S. Y. V. Chan, A. L. Hilchie, M. G. Brown, R. Anderson, and D. W. Hoskin, “Apoptosis induced by intracellular ceramide accumulation in MDA-MB-435 breast carcinoma cells is dependent on the generation of reactive oxygen species,” Experimental and Molecular Pathology, vol. 82, no. 1, pp. 1–11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. T. H. Beckham, S. Elojeimy, J. C. Cheng et al., “Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials,” Expert Opinion on Therapeutic Targets, vol. 14, no. 5, pp. 529–539, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. W. Jing, X. W. Lv, and Y. G. Du, “Potential mechanisms involved in ceramide-induced apoptosis in human colon cancer HT29 cells,” Biomedical and Environmental Sciences, vol. 22, no. 1, pp. 76–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. E. H. Schuchman, “Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease,” FEBS Letters, vol. 584, no. 9, pp. 1895–1900, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. R. G. Cutler, W. A. Pedersen, S. Camandola, J. D. Rothstein, and M. P. Mattson, “Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress - Induced death of motor neurons in amyotrophic lateral sclerosis,” Annals of Neurology, vol. 52, no. 4, pp. 448–457, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. M. M. Mielke and C. G. Lyketsos, “Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?” NeuroMolecular Medicine, vol. 22, no. 4, pp. 331–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Tong, R. Balazs, R. Soiampornkul, W. Thangnipon, and C. W. Cotman, “Interleukin-1β impairs brain derived neurotrophic factor-induced signal transduction,” Neurobiology of Aging, vol. 29, no. 9, pp. 1380–1393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. J. M. Haus, S. R. Kashyap, T. Kasumov et al., “Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance,” Diabetes, vol. 58, no. 2, pp. 337–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. P. J. Meikle, P. D. Whitfield, T. Rozaklis et al., “Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention,” Blood Cells, Molecules, and Diseases, vol. 40, no. 3, pp. 420–427, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. Z. Saeed, C. Guilbault, J. B. De Sanctis et al., “Fenretinide prevents the development of osteoporosis in Cftr-KO mice,” Journal of Cystic Fibrosis, vol. 7, no. 3, pp. 222–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Wang, B. J. Maurer, C. P. Patrick, and M. C. Cabot, “N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase,” Cancer Research, vol. 61, no. 13, pp. 5102–5105, 2001. View at Google Scholar · View at Scopus
  80. A. Erdreich-Epstein, L. B. Tran, N. N. Bowman et al., “Ceramide signaling in fenretinide-induced endothelial cell apoptosis,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49531–49537, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. F. Rehman, P. Shanmugasundaram, and M. P. Schrey, “Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity,” British Journal of Cancer, vol. 91, no. 10, pp. 1821–1828, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. M. C. Morales, G. Pérez-Yarza, N. Rementería et al., “4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated dowmstream by Bcl-2,” Free Radical Research, vol. 41, no. 5, pp. 591–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. R. M. Vilela, L. C. Lands, B. Meehan, and S. Kubow, “Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide,” International Immunopharmacology, vol. 6, no. 11, pp. 1651–1664, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Yu, Y. H. Zeidan, B. X. Wu et al., “Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 3, pp. 367–375, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Noe, D. Petrusca, N. Rush et al., “CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 3, pp. 314–323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. K. A. Becker, J. Riethmüller, A. Lüth, G. Döring, B. Kleuser, and E. Gulbins, “Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 42, no. 6, pp. 716–724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Ulrich, D. Worlitzsch, S. Viglio et al., “Alveolar inflammation in cystic fibrosis,” Journal of Cystic Fibrosis, vol. 9, no. 3, pp. 217–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. Zhang, X. Li, H. Grassmé, G. Döring, and E. Gulbins, “Alterations in ceramide concentration and pH determine the release of reactive oxygen species by Cftr-deficient macrophages on infection,” Journal of Immunology, vol. 184, no. 9, pp. 5104–5111, 2010. View at Publisher · View at Google Scholar
  89. H. Hamai, F. Keyserman, L. M. Quittell, and T. S. Worgall, “Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling,” Journal of Lipid Research, vol. 50, no. 6, pp. 1101–1108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Poschet, E. Perkett, and V. Deretic, “Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment,” Trends in Molecular Medicine, vol. 8, no. 11, pp. 512–519, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Barriere, M. Bagdany, F. Bossard et al., “Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the ph regulation of endocytic organelles,” Molecular Biology of the Cell, vol. 20, no. 13, pp. 3125–3141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. P. M. Haggie and A. S. Verkman, “Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis,” American Journal of Physiology, vol. 296, no. 6, pp. L859–L867, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. B. H. Koller, H. S. Kim, A. M. Latour et al., “Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 23, pp. 10730–10734, 1991. View at Google Scholar · View at Scopus
  94. G. Kent, R. Iles, C. E. Bear et al., “Lung disease in mice with cystic fibrosis,” Journal of Clinical Investigation, vol. 100, no. 12, pp. 3060–3069, 1997. View at Google Scholar · View at Scopus
  95. P. R. Durie, G. Kent, M. J. Phillips, and C. A. Ackerley, “Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model,” American Journal of Pathology, vol. 164, no. 4, pp. 1481–1493, 2004. View at Google Scholar · View at Scopus
  96. E. A. Eckman, C. U. Cotton, D. M. Kube, and P. B. Davis, “Dietary changes improve survival of CFTR S489X homozygous mutant mouse,” American Journal of Physiology, vol. 269, no. 5, pp. L625–L630, 1995. View at Google Scholar · View at Scopus
  97. R. Ratcliff, M. J. Evans, A. W. Cuthbert et al., “Production of a severe cystic fibrosis mutation in mice by gene targeting,” Nature Genetics, vol. 4, no. 1, pp. 35–41, 1993. View at Publisher · View at Google Scholar · View at Scopus
  98. S. J. Delaney, E. W. F. W. Alton, S. N. Smith et al., “Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations,” The EMBO Journal, vol. 15, no. 5, pp. 955–963, 1996. View at Google Scholar · View at Scopus
  99. P. Dickinson, S. N. Smith, S. Webb et al., “The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics,” Human Molecular Genetics, vol. 11, no. 3, pp. 243–251, 2002. View at Google Scholar · View at Scopus
  100. C. Guilbault, Z. Saeed, G. P. Downey, and D. Radzioch, “Cystic fibrosis mouse models,” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 1, pp. 1–7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Werner, M. E. J. Bongers, M. J. Bijvelds, H. R. De Jonge, and H. J. Verkade, “No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis,” Journal of Lipid Research, vol. 45, no. 12, pp. 2277–2286, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Gyömörey, E. Garami, K. Galley, J. M. Rommens, and C. E. Bear, “Non-CFTR chloride channels likely contribute to secretion in the murine small intestine,” Pflugers Archiv European Journal of Physiology, vol. 443, no. 1, pp. S103–S106, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. A. A. Hicks, P. P. Pramstaller, Å. Johansson et al., “Genetic determinants of circulating sphingolipid concentrations in European populations,” PLoS Genetics, vol. 5, no. 10, Article ID e1000672, 2009. View at Publisher · View at Google Scholar